drugset / Trial / NCT02601248
Study of Theliatinib (HMPL-309) in Patients With Advanced Solid Tumor
NaSingle-groupOpen-labelTreatment
Summary
First-in-human study is conducted to assess the maximum tolerated dose (MTD) and dose-limiting toxicity(DLT), safety and tolerability, pharmacokinetics (PK), and preliminary anti-tumor activity of Theliatinib .
Timeline
- Start
- 2012-10
- Primary completion
- 2016-02
- Completion
- 2016-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Theliatinib | Small molecule | 120 mg | Oral |
| Subject | Theliatinib | Small molecule | 160 mg | Oral |
| Subject | Theliatinib | Small molecule | 200 mg | Oral |
| Subject | Theliatinib | Small molecule | 220 mg | Oral |
| Subject | Theliatinib | Small molecule | 300 mg | Oral |